Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 to 75

Early wear of a Vitamin E-infused liner in a dual-mobility hip replacement

Official title: Early Wear Patterns Detected With CT RSA in Vitamin E-infused Liner Versus Conventional Highly Crosslinked Liner After Total Hip Arthroplasty With Dual Mobility Cups: a Randomized Controlled Trial

Run by Uppsala University · NCT07863557 · Data updated 2026-11-12

This study tests whether a Vitamin E-infused liner in a dual-mobility hip implant wears as little as a conventional liner over two years in adults needing hip replacement.

More Osteoarthritis trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment40 (estimated)
SponsorUppsala University
Academic / other
Locations1 site (Uppsala, Uppsala County)
StatusRecruiting
StartedOctober 8, 2026
Main results expectedOctober 1, 2033
Study endsOctober 1, 2033
Registry record updatedOctober 9, 2026
Trial IDNCT07863557 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18-75 with symptomatic hip osteoarthritis, osteonecrosis, or dysplasia requiring total hip arthroplasty and eligible for a dual mobility cup.

Probably not a fit

Patients outside the age range, with cognitive impairment, or without eligibility for a dual-mobility cup may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, randomized, double-blind, non-inferiority trial conducted at Uppsala University Hospital. It compares a BiMobile dual-mobility cup with a Vitamin E-infused polyethylene liner to a conventional polyethylene liner in adults with symptomatic hip OA, osteonecrosis, or dysplasia undergoing total hip arthroplasty. Wear and migration will be measured using CT-based radiostereometric analysis over two years, with extended follow-up to five years for secondary outcomes. The study aims to determine if the VEPE liner is not worse than the conventional liner in early wear, while also monitoring safety, patient satisfaction, and functional outcomes.

Why it matters

Potential benefit: If successful, patients could benefit from reduced wear and potentially longer-lasting hip implants with fewer revisions.

How similar studies have gone: Previous studies of dual-mobility implants have reported low wear and good survival, though evidence specific to VEPE liners in this context is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18-75 years
* Written informed consent
* Eligible for a Total Hip Arthroplasty according to local guidelines and appropriate candidate for a dual mobility concept
* Diagnosis: Symptomatic osteoarthritis, osteonecrosis, or dysplasia of the hip requiring a hip replacement

Exclusion Criteria:

* Confirmed dementia or cognitive impairment
* Unwillingness to give written informed consent
* Age \<18 or \>75 years
* Hip fracture (traumatic or pathological) in need of a Total Hip Arthroplasty
* Patients who are not deemed suitable for a THA with a Dual Mobility Cup according to local guidelines and routines
* Comorbidities that are contraindicators for hip replacement surgery

Where it's running

  • Uppsala University Hospital
    Uppsala, Uppsala County, Sweden
    Recruiting

Study contacts

  • Principal investigator: Anders Brüggemann, MD, PhD — Department of Surgical Sciences, Uppsala University
  • Study coordinator: Anders Brüggemann, MD, PhD
  • Email: anders.bruggemann@uu.se
  • Phone: +46 707-498242

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.